期刊
CURRENT OPINION IN PEDIATRICS
卷 34, 期 2, 页码 223-228出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOP.0000000000001113
关键词
childhood renovascular hypertension; granulomatous vasculitis; Takayasu arteritis
类别
资金
- Liliane Barbarosh Pediatric Renal Research and Educational Fund at the University of Miami
This review aims to provide a comprehensive understanding of the pathophysiology, cause, and epidemiology of Takayasu arteritis, as well as the diagnosis, prognosis, and treatment in children. Although the exact etiology of this disease is not fully understood, it is believed to have an autoimmune basis and genetic predisposition. Unlike in adults, Takayasu arteritis in children has distinct diagnostic criteria and clinical manifestations. Current treatment algorithms involve the use of less toxic contemporary biologic agents and early diagnosis for better long-term prognosis.
Purpose of review Takayasu arteritis is a rare chronic granulomatous large vessel vasculitis that predominantly affects the aorta and its branches. The purpose of this review is to unite the current knowledge regarding the pathophysiology, cause, and epidemiology as well as diagnosis, prognosis, and treatment of this condition in children. Recent findings Although the etiopathogenesis is not fully understood, studies suggest an autoimmune basis for the disease as well as a genetic predisposition. It is a disease primarily affecting young women with up to a third of cases with onset in childhood. There are distinct features of childhood-onset Takayasu arteritis (cTA) that merit this separate review. Diagnostic criteria and clinical manifestations are unique in pediatric patients with renovascular hypertension being the most prevalent presentation. Traditional treatments involving high-dose corticosteroids and cytotoxic agents are being reconsidered for less toxic contemporary biologic agents. Current algorithms for treatment include early introduction of corticosteroid-sparing agents, such as methotrexate or mycophenolate as well as tumor necrosis factor-alpha (TNF-alpha) inhibitor (infliximab, adalimumab) and/or interleukin-6 (IL-6) receptor inhibitor (tocilizumab). Early diagnosis of cTA with goals to develop effective and well tolerated treatment paradigms are essential to improve the long-term prognosis of this rare and devastating disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据